Search
Selenomethionine
go.drugbank.com/drugs/DB11142ApprovedInvestigationalSelenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans.
Eniluracil
go.drugbank.com/drugs/DB03516InvestigationalEniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.
Picoplatin
go.drugbank.com/drugs/DB04874InvestigationalIt causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.
MDX-1303
go.drugbank.com/drugs/DB05945InvestigationalMDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalIt is developed by AstraZeneca and is currently in phase I/II trials.
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Lesopitron
go.drugbank.com/drugs/DB04970ExperimentalLesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]
Oral Polio Vaccine
go.drugbank.com/drugs/DB15864InvestigationalStrains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with … The vaccine is created by weakening the wildtype before being placed into the oral vaccine.
Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...